11,892 Shares in Smith & Nephew SNATS, Inc. (NYSE:SNN) Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC bought a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The fund bought 11,892 shares of the medical equipment provider's stock, valued at approximately $335,000.

Other large investors have also recently made changes to their positions in the company. Hara Capital LLC boosted its stake in shares of Smith & Nephew SNATS by 391.4% during the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock worth $60,000 after purchasing an additional 1,957 shares during the period. US Bancorp DE boosted its stake in shares of Smith & Nephew SNATS by 21.8% during the 4th quarter. US Bancorp DE now owns 13,604 shares of the medical equipment provider's stock worth $334,000 after purchasing an additional 2,437 shares during the period. Jones Financial Companies Lllp boosted its position in Smith & Nephew SNATS by 18.2% in the 4th quarter. Jones Financial Companies Lllp now owns 11,696 shares of the medical equipment provider's stock valued at $287,000 after buying an additional 1,797 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Smith & Nephew SNATS by 22.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 33,305 shares of the medical equipment provider's stock valued at $819,000 after buying an additional 6,106 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Smith & Nephew SNATS in the 4th quarter valued at about $4,992,000. 25.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

SNN has been the subject of several research reports. HSBC cut shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Canaccord Genuity Group upped their price target on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a "hold" rating in a research note on Thursday, May 1st. Finally, Hsbc Global Res lowered shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Six equities research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $28.00.

Smith & Nephew SNATS Price Performance

Shares of NYSE SNN traded down $0.23 during mid-day trading on Monday, reaching $30.06. The company's stock had a trading volume of 634,373 shares, compared to its average volume of 819,285. The stock has a 50-day moving average of $29.37 and a two-hundred day moving average of $27.54. The stock has a market capitalization of $13.16 billion, a P/E ratio of 13.91, a P/E/G ratio of 0.93 and a beta of 0.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.33 and a current ratio of 2.89. Smith & Nephew SNATS, Inc. has a 1-year low of $23.69 and a 1-year high of $31.72.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.